Article Figures & Data
Figures
- FIGURE 1.
Kaplan–Meier analyses of patients grouped according to RECIP 1.0, PCWG3 PSA, and combined assessment for PD or non-PD. Patients with PD according to RECIP 1.0 (OS, 9 mo vs. 17 mo) (A), PCWG3 PSA (OS, 9 mo vs. 19 mo) (B), and combined PD (OS, 8 mo vs. 19 mo) (C) showed shorter OS. However, only segregations based on PCWG3 and PCWG3 with RECIP 1.0 reached significance.
Tables
Disease stage Description RECIP 1.0* PD >20% increase of tumor volume with appearance of new lesions StD <30% decrease in tumor volume with or without appearance of new lesions, or ≥30% decrease in tumor volume with appearance of new lesions, or <20% increase in tumor volume with or without appearance of new lesions, or ≥20% increase in tumor volume without appearance of new lesions Partial response >30% decrease in tumor volume without appearance of new lesions Complete response Absence of any PSMA uptake on follow-up PET scan PCWG3 PD ≥25% increase in PSA levels at interim PET Response ≥50% decrease in PSA levels at interim PET ↵* New lesions were defined as tumor uptake of PSMA ligand higher than that of surrounding background, with SUVmax higher than blood-pool SUVmax, which was not present at baseline PET.
Parameter Data Clinical variables Age at first cycle of PSMA RLT (y) 72 (46–88) IntervalDiagnosis-RLT (mo) 77 (9–274) Treatment cycles per patient 4 (2–8) Cumulative activity (GBq) 19.1 (11.2–50.9) Gleason score 9 (6–10) Baseline laboratory values PSA (ng/mL) 107.0 (2.9–3,590) CRP (mg/dL) 0.42 (0.1–12.7) LDH (U/L) 245.0 (152–593) Hemoglobin (g/dL) 12.0 (7.7–14.8) AP (U/L) 127.0 (39.0–3,330) PSMA-TV (cm3) 730.7 (5.0–3,301) TL-PSMA (cm3) 5135 (20.2–33,441) SUVmax 39.7 (6.6–190.9) SUVpeak 19.3 (4.3–94.1) SUVmean 7.6 (4.0–16.3) Sites of metastases (n) (total n = 73) Bone 72 (98.6%) Lymph node 49 (67.1%) Visceral 28 (38.4%) Liver 16 (21.9%) Lung 11 (15.1%) Prior treatments (%) Radical prostatectomy 41.1 Primary radiation therapy to prostate 13.7 Antihormonal treatment 100 Enzalutamide 79.5 Abiraterone 68.5 Chemotherapy 79.5 223Ra 2.7 IntervalDiagnosis-RLT = time between initial diagnosis and first RLT; CRP = C-reactive protein; LDH = lactate dehydrogenase; AP = alkaline phosphatase.
Continuous data are median and range
Variables Data Reduction Change in PSMA-TV (cm3) +27.2 (−66.9–8,934) 30 (41.1%) Bone +28.1 (−71.4–1,699) Lymph node −21.8 (−100–5,835) Change in TL-PSMA (cm3) −0.8 (−86.6–5,627) 37 (50.7%) Change in SUVmax −30.1 (−83.7–43.7) 61 (83.6%) Change in SUVpeak −31.6 (−86.7–60.3) 58 (79.5%) Change in SUVmean −25.5 (−71.3–38.1) 62 (84.9%) Change in PSA +1.9 (−99.1–870) 36 (49.3%) Continuous data are median and range. Quantitative data are number of patients and percentage.
Parameter Univariable Multivariable HR 95% CI C-index P HR 95% CI P Change in PSMA-TV (%) 1.003 1.000–1.005 0.68 0.03 1.001 0.9972–1.004 0.62 Change in TL-PSMA (%) 1.002 1.000–1.004 0.65 0.13 Change in SUVmean (%) 1.000 0.9800–1.018 0.51 0.90 Change in SUVpeak (%) 1.005 0.9945–1.015 0.54 0.34 Change in SUVmax (%) 1.005 0.9923–1.017 0.54 0.46 Change in PSA (%) 1.004 1.002–1.007 0.69 0.001 1.004 1.000–1.006 0.03 New metastases 1.902 0.8780–4.249 0.60 0.10 1.023 0.4469–2.536 0.96 RECIP 1.0 PD* 2.100 0.9611–4.590 0.60 0.06 PCWG3 PD* 2.288 1.018–5.100 0.63 0.04 RECIP+PCWG3 PD* 3.297 1.493–7.791 0.69 0.004 Any PSA response 0.5026 0.2278–1.092 0.61 0.08 PSA response >50% 0.4339 0.1720–0.9728 0.63 0.05 ↵* Tested vs. all non-PD patients in entire cohort.
Supplemental Data
Files in this Data Supplement:
